Katherine Roberts, MD
Endocrinology, Diabetes & Metabolism · Williamsburg, VANPI 1437348851
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 227 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$842
- Corcept Therapeutics$650
- Mannkind Corporation$357
- Lilly USA, LLC$311
- AbbVie$295
- Novo Nordisk$292
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,800100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 24 | $842 |
| Corcept Therapeutics | 29 | $650 |
| Mannkind Corporation | 25 | $357 |
| Lilly USA, LLC | 19 | $311 |
| AbbVie | 13 | $295 |
| Novo Nordisk | 15 | $292 |
| Insulet Corporation | 7 | $252 |
| AstraZeneca(2 entities) | 13 | $240 |
| Radius Health, Inc. | 10 | $184 |
| Acella Pharmaceuticals, LLC | 4 | $124 |
| Shire North American Group Inc | 10 | $116 |
| Kyowa Kirin, Inc. | 6 | $108 |
| Amneal Pharmaceuticals LLC | 7 | $106 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| Exelixis Inc. | 1 | $87 |
| Recordati_rare_diseases_inc. | 5 | $85 |
| Antares Pharma, Inc. | 4 | $69 |
| Halozyme Inc | 3 | $63 |
| Cequr Corporation | 1 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Bayer | 3 | $58 |
| Boehringer Ingelheim | 3 | $55 |
| Medtronic | 2 | $54 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| Abbott | 1 | $24 |
| BETA Bionics, Inc. | 2 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Senseonics, Incorporated | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,812 in reported general payments places this provider in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $196,450 |
| JardianceEmpagliflozin | 86 | $87,937 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $43,039 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $41,621 |
| TrulicityDulaglutide | 20 | $37,025 |
| CreonLipase/Protease/Amylase | 24 | $32,355 |
| FarxigaDapagliflozin Propanediol | 14 | $21,756 |
| JanuviaSitagliptin Phosphate | 18 | $19,054 |
| SynthroidLevothyroxine Sodium | 226 | $18,005 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $16,552 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $14,784 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $9,408 |
| Novolog FlexpenInsulin Aspart | 41 | $8,219 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 61 | $7,827 |
| Cabergoline | 43 | $6,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $292 | $200,931148 claims |
| Boehringer IngelheimJardiance | $55 | $87,93786 claims |
| AbbVieCreon, Synthroid, Armour Thyroid | $295 | $55,233322 claims |
| Lilly USA, LLCTrulicity, Humalog, Insulin Lispro | $311 | $45,12462 claims |
| AstraZenecaFarxiga | $240 | $21,75614 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $106 | $3,472266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Williamsburg
- Karen KnudsenWilliamsburg$6K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.